Regeneron selloff ‘overdone’ with pipeline catalysts coming, says Morgan Stanley

Morgan Stanley lowered the firm’s price target on Regeneron (REGN) to $1,184 from $1,235 and keeps an Overweight rating on the shares following a Q3 miss for high dose Eylea and a delay to the new pre-filled syringe. However, following the recent selloff in shares, the firm sees a buying opportunity ahead of upcoming pipeline catalysts for Regeneron, the analyst tells investors.